DATE: November 28, 2017
TIME: 06:00am PST, 08:00am CST, 09:00am EST, 3:00pm CEST
As global healthcare changes, healthcare institutions are being tasked with handling a higher volume of patients, rising costs, and heightened performance pressures. Laboratories, in particular, are under new demands to drive even greater healthcare value with fewer and fewer resources.
To address such complex and interrelated challenges, Abbott has developed a unified next-generation family of diagnostic systems designed to help labs achieve measurably better healthcare performance across the laboratory: Alinity.
In this web-series, we’ll learn about Abbott’s multi-pronged, collaborative, and technology-enabled approach and how it shapes the all-new Alinity ci-series clinical chemistry and immunoassay systems. This first discussion with Jennifer Hollenstein, Brittany Dressler, and Jose Santiago, PhD will also share first-look, preliminary data from three Alinity ci-series familiarization sites and explore:
- The outcome of productivity and reliability studies versus the newly developed Alinity clinical chemistry and immunoassay systems and legacy ARCHITECT systems
- Perspectives and insights on being one of the first Alinity users from evaluation studies
- The flexibility of such a compact, scalable system and its ability to boost productivity in a growing private laboratory
And don’t miss our next series that will look at Alinity ci-series’ features for a better understanding of how it can address your needs and help your lab deliver measurably better healthcare performance.
*Alinity is only available in select markets and is not commercially available in the US.